About Artegraft
Artegraft is a Healthcare company based in North Brunswick (United States) founded in 1993, and was acquired by LeMaitre Vascular in June 2020. Bovine carotid artery grafts are provided as medical devices. Its chief executive, as recorded, is Richard Gibson. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Avinger, Pathway Medical Technologies and Intact Vascular; 3 of its 3 listed competitors have raised funding.
Company details
Artegraft was founded in 1993 and is headquartered in North Brunswick, United States. Biological bovine carotid artery grafts are offered by the company as alternatives to synthetic vascular grafts. These devices consist of a processed biological fibrous matrix designed for surgical applications in vascular procedures. Operations focus on the development and distribution of such medical implants within the healthcare sector.
- Headquarters North Brunswick, United States
- Stage Acquired
- SectorsHealthcare
- Website artegraft.com
- Acquired by LeMaitre Vascular (Jun 2020)
- Investors
- Acquired byLeMaitre Vascular
(Jun 2020)
Investors in Artegraft
Artegraft has secured backing from 1 investor. Prominent investors backing the company include LeMaitre Vascular.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Devices for peripheral vascular disease treatment are developed and marketed. | 1983 | lemaitre.com | Burlington, United States |
Investor details for Artegraft
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Artegraft
1 people are tracked at Artegraft (1 in leadership).
| Name | Role | Group |
|---|---|---|
Richard Gibson | CEO | Leadership |
Complete people profiles for Artegraft
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Artegraft
2 dated milestones of Artegraft across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Artegraft is founded.
- Exit Acquired by LeMaitre Vascular.
Competitors of Artegraft
Artegraft has 3 listed competitors in our database, 3 of them funded. They include Avinger, Pathway Medical Technologies and Intact Vascular.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| avinger.com | 2007 | Redwood, United States | $170.85M | 80 | Provider of image-guided catheter-based products for peripheral artery disease | |
| pathwaymedical.com | 1998 | Kirkland, United States | $101.93M | 158 | Smart devices are provided to clear peripheral arterial blockages. | |
| intactvascular.com | 2011 | Wayne, United States | $123.4M | 64 | Implants for repairing arteries after angioplasty are developed. |
Detailed competitors of Artegraft
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Artegraft (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Artegraft
Complete news archive for Artegraft
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Artegraft
Artegraft was founded in 1993.
Artegraft is headquartered in North Brunswick, United States. It is registered at North Brunswick, New Jersey, United States.
Richard Gibson is the CEO of Artegraft, as recorded in our data.
Artegraft was founded in 1993 and is headquartered in North Brunswick, United States. Biological bovine carotid artery grafts are offered by the company as alternatives to synthetic vascular grafts. These devices consist of a processed biological fibrous matrix designed for surgical applications in vascular procedures. Operations focus on the development and distribution of such medical implants within the healthcare sector.
Artegraft's top competitors include Avinger, Intact Vascular and Pathway Medical Technologies.
Artegraft has 1 investor. Key investors include LeMaitre Vascular.
Yes. Artegraft was acquired by LeMaitre Vascular in June 2020.